Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
2.050
+0.060 (3.02%)
At close: Oct 31, 2025, 4:00 PM EDT
2.090
+0.040 (1.95%)
After-hours: Oct 31, 2025, 4:24 PM EDT
Climb Bio Employees
As of December 31, 2024, Climb Bio had 18 total employees, including 17 full-time and 1 part-time employees. The number of employees increased by 7 or 63.64% compared to the previous year.
Employees
18
Change (1Y)
7
Growth (1Y)
63.64%
Revenue / Employee
n/a
Profits / Employee
-$2,597,667
Market Cap
138.92M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | 7 | 63.64% |
| Dec 31, 2023 | 11 | -32 | -74.42% |
| Dec 31, 2022 | 43 | 12 | 38.71% |
| Dec 31, 2021 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CLYM News
- 11 days ago - Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy - GlobeNewsWire
- 15 days ago - Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 - GlobeNewsWire
- 4 weeks ago - Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN - GlobeNewsWire
- 2 months ago - Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025 - GlobeNewsWire
- 2 months ago - UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences - GlobeNewsWire
- 2 months ago - Climb Bio to Present at Upcoming September 2025 Investor Conferences - GlobeNewsWire
- 2 months ago - Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire